Type of security: Stock
Sector: Health Care
Industry: Medical/Dental Instruments
Market Capitalization: 37.46 B
The data is delayed by 15 minutes.
Description: Becton, Dickinson and Company, a medical technology company, develops, manufactures, and sells medical devices, instrument systems, and reagents worldwide. The company?s BD Medical segment produces medical devices, such as needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for use in the treatment of diabetes; prefillable drug delivery systems; anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; and generic prefilled injectables. Its BD Diagnostics segment provides products for the collection and transportation of diagnostics specimens; and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections, and cancers. This segment?s products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood and tuberculosis culturing systems; molecular testing systems; microorganism identification and
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||212.2 M||EPS||8.3||EPS Growth - 4 Quarters||-54.75%||EPS Growth - Q/Q||-16.67%|
|EPS Growth - Y/Y||-15.77%||Sales Growth - 4 Quarters||-4.96%||Sales Growth - Q/Q||0%||P/E||23.05|
|P/E To EPS Growth||-1.07||P/S||4.43||P/BV||5.23||Price/Cash Per Share||17.6|
|Price/Free Cash Flow||32.46||ROA||3.81%||ROE||15.07%||ROI||5.32%|
|Current Ratio||1.56||Quick Ratio||1.05||Long Term Debt/Equity||4.85||Debt Ratio||0.63|
|Gross Margin||50.87%||Operating Margin||17.6%||Net Profit Margin||12.75%||Dividend Payout Ratio||-40.96%|
|Cash From Financing Activities||7.39 B||Cash From Investing Activities||-7.83 B||Cash From Operating Activities||514 M||Gross Profit||1.05 B|
|Net Profit||216 M||Operating Profit||293 M||Total Assets||28.29 B||Total Current Assets||7 B|
|Total Current Liabilities||4.5 B||Total Debt||13.84 B||Total Liabilities||21.13 B||Total Revenue||2.05 B|
|High 52 week||263.51||Low 52 week||209.85||Last close||227.62||Last change||1.08%|
|RSI||37.42||Average true range||5.37||Beta||0.56||Volume||378.9 K|
|Simple moving average 20 days||-1.43%||Simple moving average 50 days||-5.15%||Simple moving average 200 days||-5.97%|
|Performance Week||1.31%||Performance Month||1.1%||Performance Quart||-7.76%||Performance Half||-2.62%|
|Performance Year||1.55%||Performance Year-to-date||1.02%||Volatility daily||1.29%||Volatility weekly||2.9%|
|Volatility monthly||5.93%||Volatility yearly||20.56%||Relative Volume||181.88%||Average Volume||1.33 M|
|New High||New Low|
2019-06-13 21:33:46 | Here is What Hedge Funds Think About Becton, Dickinson and Company BDX
2019-06-12 13:16:10 | Is There Now An Opportunity In Becton, Dickinson and Company NYSE:BDX?
2019-06-11 08:00:32 | See what the IHS Markit Score report has to say about Becton Dickinson and Co.
2019-06-10 08:00:08 | See what the IHS Markit Score report has to say about Becton Dickinson and Co.
2019-06-08 09:30:01 | Why Is Becton Dickinson BDX Up 3.7% Since Last Earnings Report?
2019-06-08 04:47:34 | Is Budimex SA's WSE:BDX ROE Of 35% Impressive?
2019-06-05 08:00:13 | See what the IHS Markit Score report has to say about Becton Dickinson and Co.
2019-06-04 14:51:00 | BD Announces Pricing and Upsizing of Tender Offers
2019-06-03 20:11:00 | BD Announces Early Tender Results
2019-05-31 16:05:00 | BD to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
2019-05-22 08:59:52 | Would Becton, Dickinson and Company NYSE:BDX Be Valuable To Income Investors?
2019-05-20 03:46:00 | Becton, Dickinson and Company Announces Tender Offers for Outstanding Debt Securities
2019-05-16 15:12:00 | Becton, Dickinson Muscles Through a Tough Quarter
2019-05-14 13:15:00 | The Charts of Becton, Dickinson Need More 'Work' Before a Rally
2019-05-14 07:30:37 | Jim Cramer Gives His Opinion On Becton Dickinson, Fox, Puma Biotech And More
2019-05-13 04:17:48 | Is Budimex SA's WSE:BDX Balance Sheet Strong Enough To Weather A Storm?
2019-05-09 15:52:50 | Edited Transcript of BDX earnings conference call or presentation 9-May-19 12:00pm GMT
2019-05-09 12:23:30 | Becton Dickinson & Co. BDX Q2 2019 Earnings Call Transcript
2019-05-09 10:02:02 | Stock Market News For May 9, 2019
2019-05-09 09:46:00 | Becton Dickinson's stock drops after profit, revenue growth outlook cut
2019-05-09 08:39:12 | Becton, Dickinson BDX Q2 Earnings Beat, Revenues Fall Y/Y
2019-05-09 06:08:36 | Becton Dickinson: Fiscal 2Q Earnings Snapshot
2019-05-09 06:00:00 | BD Announces Results for 2019 Second Fiscal Quarter; Updates Fiscal 2019 Guidance
2019-05-08 16:49:00 | Becton, Dickinson Expected to Earn $2.58 a Share
2019-05-07 08:00:15 | See what the IHS Markit Score report has to say about Becton Dickinson and Co.
2019-05-03 08:29:12 | Can BD Medical Drive Becton, Dickinson's BDX Q2 Earnings?
2019-05-01 16:15:00 | BD to Present at the Bank of America Merrill Lynch 2019 Healthcare Conference
2019-04-30 11:10:54 | Does Becton, Dickinson and Company's NYSE:BDX CEO Pay Compare Well With Peers?
2019-04-30 08:00:28 | See what the IHS Markit Score report has to say about Becton Dickinson and Co.
2019-04-29 16:15:00 | BD Board Declares Dividends
2019-04-24 15:36:07 | Top Analyst Reports for Celgene, Schlumberger & Becton, Dickinson
2019-04-22 14:00:06 | Top Stock Reports for IBM, Honeywell & American Express
2019-04-17 15:14:50 | 5 Dividend Stocks Perfect for Retirees
2019-04-10 14:12:06 | Top Stock Reports for Eli Lilly, Altria & Becton Dickinson
2019-04-09 09:51:01 | BD Introduces New Product to Reduce the Risk of Sepsis
2019-04-08 12:22:28 | Here’s why Becton, Dickinson and Company’s NYSE:BDX Returns On Capital Matters So Much
2019-04-05 09:33:01 | Here's Why You Should Hold Becton, Dickinson Stock for Now
2019-04-04 16:30:00 | BD Announces Live Webcast Of Second Fiscal Quarter Earnings Conference Call
2019-03-27 18:53:18 | Were Hedge Funds Right About Exiting Becton, Dickinson and Company BDX?
2019-03-25 10:49:02 | BD Remains Confident About LUTONIX DCB Despite FDA Letter